NCT00667329View on ClinicalTrials.gov

Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and Rituximab

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

July 9, 1999

Primary Completion Date

February 10, 2022

Study Completion Date

February 10, 2022

Conditions
Lymphoma
Interventions
DRUG

2CdA

1.5 mg/m\^2 subcutaneous injection three times daily x 7 days.

DRUG

Cyclophosphamide

40 mg/m\^2 PO twice daily x 7 days.

DRUG

Rituximab

375 mg/m\^2 IV once weekly x 4 weeks.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT00667329 - Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and Rituximab | Biotech Hunter | Biotech Hunter